{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:07:38Z","timestamp":1789222058496,"version":"build-2803163510"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Obstet Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To compare the safety and efficacy of 12 versus 24-h postpartum magnesium sulfate (MgSO\n                      <jats:sub>4<\/jats:sub>\n                      ) infusion protocol in women with severe preeclampsia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study analyzed patient outcomes before and after a postpartum magnesium protocol change for cases of severe preeclampsia: 24-h MgSO\n                      <jats:sub>4<\/jats:sub>\n                      (Feb\u2013Sep 2021) versus 12-h MgSO\n                      <jats:sub>4<\/jats:sub>\n                      (Sep 2021\u2013Feb 2023). The primary outcome was eclampsia; secondary outcomes included magnesium toxicity, maternal complications, postpartum length of stay, ambulation time, and time to Foley catheter removal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics were similar. No cases of eclampsia occurred in either protocol. Magnesium toxicity and maternal complications were comparable. Notably, 10 out of the 75 patients in the 12-h protocol required magnesium extension due to persistent preeclampsia symptoms. However, the 12-h protocol was associated with shorter postpartum stay, earlier ambulation, and earlier time to Foley catheter removal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The 12-h MgSO\n                      <jats:sub>4<\/jats:sub>\n                      protocol is as safe and effective as the 24-h protocol. There were no differences in rates of convulsion or negative maternal outcomes between the two protocols.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1753495x251388841","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:31:28Z","timestamp":1763490688000},"page":"162-167","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing a 12 versus 24-h postpartum IV magnesium protocol for preeclampsia with severe features at an academic-affiliated community hospital"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6604-0941","authenticated-orcid":false,"given":"Jordan","family":"Beacham","sequence":"first","affiliation":[{"name":"Thomas Jefferson University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3844-1832","authenticated-orcid":false,"given":"Orchideh","family":"Alexander","sequence":"additional","affiliation":[{"name":"Abington Jefferson Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Smith","sequence":"additional","affiliation":[{"name":"Abington Jefferson Health"},{"name":"Division of Maternal Fetal Medicine, Abington Jefferson Health, Abington, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174246"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0965539511000040"},{"key":"e_1_3_2_4_2","article-title":"Magnesium sulphate and other anticonvulsants for women with pre-eclampsia","volume":"2010","author":"Duley L","year":"2010","unstructured":"Duley L, G\u00fclmezoglu AM, Henderson-Smart DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010; 2010: CD000025.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_5_2","article-title":"ACOG Practice Bulletin No. 222: gestational hypertension and preeclampsia","volume":"135","author":"American College of Obstetricians and Gynecologists","year":"2020","unstructured":"American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 222: gestational hypertension and preeclampsia. Obstet Gynecol 2020; 135: e237\u2013e260.","journal-title":"Obstet Gynecol"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-13-195"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14181"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.13082"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2015.1083547"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-024-03271-0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038055"},{"key":"e_1_3_2_12_2","unstructured":"United Nations. The UN commission on essential drugs for maternal and child health report. UNFPA. https:\/\/www.unfpa.org\/sites\/default\/files\/pub-pdf\/Final%20UN%20Commission%20Report_14sept2012.pdf. 2012 September 14."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-13-34"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Witlin AG Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews. Centre for Reviews and Dissemination (UK). 1998.","DOI":"10.1097\/00006250-199811000-00028"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14296"},{"key":"e_1_3_2_16_2","article-title":"12 Versus 24 hours of postpartum magnesium sulfate for seizure prophylaxis: a cost-effective analysis","volume":"230","author":"Robinson A","year":"2024","unstructured":"Robinson A, Curl O, Doshi U, et al. 12 Versus 24 hours of postpartum magnesium sulfate for seizure prophylaxis: a cost-effective analysis. J Obstet Gynaecol 2024; 230: S1012.","journal-title":"J Obstet Gynaecol"}],"container-title":["Obstetric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X251388841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753495X251388841","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753495X251388841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:47:53Z","timestamp":1789220873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753495X251388841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/1753495X251388841"],"URL":"https:\/\/doi.org\/10.1177\/1753495x251388841","relation":{},"ISSN":["1753-495X","1753-4968"],"issn-type":[{"value":"1753-495X","type":"print"},{"value":"1753-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}